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Background: Given DCBT may improve engraftment &
protect against relapse, we have adopted DCBT for both
children & adults with acute leukemia, myelodysplasia
(MDS), & myeloproliferative diseases (MPD). However,
determinants of disease-free survival (DFS) after DCBT have
yet to be established.
Methods: We analyzed the DFS of 92 DCBT recipients with
acute leukemia in morphologic remission or aplasia (n¼ 83),
& MDS/MPD with  5% blasts at work-up (n ¼ 9) trans-
planted from 10/2005-5/2012. Nearly all patients had high-
risk disease.
Results: Children [n ¼ 27, median age 7 years (range 0.9-15),
medianweight 30 kg (range 8-72)] were 33% European & 26%
CMV sero-positive with diagnoses of AML (or biphenotypic)
in 44%, ALL in 52%, MDS/MPD in 4%, & all received high-dose
conditioning. Their grafts had a median infused TNC x 107/kg
of 4.4 (larger unit) & 2.9 (smaller unit), & 4% of units were 6/6
HLA-A,-B antigen,-DRB1 allele matched, 61% 5/6, & 35% 4/6.
Adults [n ¼ 65, median age 47 years (range 16-69), median
weight 69 kg (range 45-105)] were 48% European & 68% CMV
sero-positive. Diagnoses in adult patients were AML (or
biphenotypic) in 62%, ALL in 26%, & MDS/MPD in 12%. Forty-
two percent of adults received high-dose & 58% reduced
intensity conditioning. Their units had a median infused
TNC/kg of 2.7 & 2.0, respectively, & 3% were 6/6 HLA-
matched, 44% 5/6, & 53% 4/6. All patients received
calcineurin-inhibitor/mycophenolate mofetil immunosup-
pression. Sustained donor neutrophil engraftment was seen
in 93% of children (median neutrophil recovery at 20 days) &
97% of adults (median 25 days). Platelet engraftment was
seen in 85% of children (median recovery at 50 days) & 83% of
adults (median 48 days). The incidence of day 180 grade II-IV
acute GVHD was 41% in children & 60% in adults. Day 100
TRM was 7% in children & 15% in adults. The 2-year relapse
incidence was 17% in children & 7% in adults. With a median
33month (range 3-84) follow-up of survivors, the 2-year DFS
is 72% in children & 65% in adults. Univariate analysis of
variables potentially inﬂuencing 2-year DFS (Table 1)
demonstrated there were no differences according to patient
age, ancestry, remission status, conditioning intensity,
engrafting unit-recipient HLA-match, or engrafting unit
infused TNC dose/kg. However, patients who were CMVTable 1
Comparison 2-Year DFS P value
Age 0-15 years (n ¼ 27) 72% 0.29
>16 years (n ¼ 65) 65%
Ancestry Europeans (n ¼ 40) 69% 0.90
Non-Europeans (n ¼ 52) 66%
Remission Status CR1 (n ¼ 49) 65% 0.92
All others (n ¼ 43) 69%
Conditioning
Intensity
High-dose (n ¼ 54) 70% 0.50
Reduced intensity (n ¼ 38) 62%
Recipient CMV
Sero-status
CMV+ (n ¼ 51) 53% 0.01
CMV- (n ¼ 41) 81%
Engrafting Unit -
Recipient
HLA-match
4/6 (n ¼ 36) 74% 0.96
5-6/6 (n ¼ 51) 69%
2-6/10 (n ¼ 50) 69% 0.87
7-9/10 (n ¼ 37) 72%
Engrafting Unit
Infused TNC dose
< 3.0  107/kg (n ¼ 62) 72% 0.90
 3.0 x 107/kg (n ¼ 25) 68%seronegative had a higher 2-year DFS (81% vs 53%, P ¼ .01).
Multivariate analysis revealed recipient CMV serostatus was
a predictor of DFS independent of patient age, & its effect was
mediated by an inﬂuence on TRM.
Conclusions: DCBT can achieve high & comparable DFS in
both European & non-Europeanpatients with acute leukemia
with a low rate of relapse. While the mechanism of the
mortality risk associated with CMV seropositivity requires
further investigation, our ﬁndings support DCBT as an
immediate alternative therapy for high-risk acute leukemia in
patients without suitable unrelated volunteer donors.468
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The association between HLA-DP and hematopoietic stem
cell transplantation (HCT) outcomes is still questionable. In
the present study, we examined 80 patients who underwent
ﬁrst allogeneic HCT between the years of 2005-2008 and
were followed up for at least 2 years post transplant. These
patients were 10/10 matched for HLA-A, -B, -C, -DR and -DQ
at high resolution using Sequence Speciﬁc Priming (SSP) and/
or Sequence Based Typing (SBT). We analyzed the impact of
donor/recipient (D/R) mismatches at HLA-DPA1 and HLA-
DPB1 on different HCT outcomes including aGVHD, cGVHD,
and risk of disease relapse in a single center study. Addi-
tionally, we classiﬁed HLA-DPB1 mismatches as permissive
or non-permissive according to a previously described TCE4
algorithm and attempted to conﬁrm its efﬁcacy. Each cate-
gorical testing variable were compared with the different
clinical end points by 2-tailed Fischer's exact test. The
magnitude of effect was estimated by risk ratios and their
95% conﬁdence intervals. “p” value 0.05 (two-sided) was
considered signiﬁcant. A total of 160 alleles were observed at
HLA-DPA1 and 159 alleles were observed at HLA-DPB1 locus.
HLA-DPA1 and DPB1 allelic frequencies in the study pop-
ulationwere not signiﬁcantly different from those previously
observed in other Caucasian populations. At DPA1 locus, D/R
mismatching was observed in 15% of D/R pairs, however
almost all of them were mismatched at the level of single
allele. Since only one patient was mismatched for both DPA1
alleles, the effect of DPA1 mismatches were not analyzed for
single or double mismatches. At the DPB1 locus, 44% D/R
pairs were found mismatched, including 24% for single allele
and 20% for both alleles. No variables analyzed (allelic or
non-permissive mismatches) were signiﬁcantly associated
with any transplant outcomes evaluated in this patient
cohort. Our study did not conﬁrm the association between
HLA-DP mismatches and HCT outcomes. The TCE4 algorithm
also did not yield signiﬁcant advantageous results. Our
results are in accord with a recent French study but dis-
concordant with various studies conducted elsewhere,
including the United States and the United Kingdom. Further
molecular study of HLA-DP in the clinical setting is war-
ranted to further elucidate the role of this gene and its mis-
matching on HCT outcome.
